Header Logo

Connection

MILIND JAVLE to Triple Negative Breast Neoplasms

Back to Details
This is a "connection" page, showing publications MILIND JAVLE has written about Triple Negative Breast Neoplasms.
MILIND JAVLE
Connection Strength
0.480
Triple Negative Breast Neoplasms
  1. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.480
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.